Trials / Not Yet Recruiting
Not Yet RecruitingNCT07156539
A Phase 3 Study of HS-20094 in Patients With T2DM
A Study of HS-20094 Versus Dulaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabete
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 546 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of HS-20094 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Dulaglutide QW for 44 weeks and 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-20094 Injection | HS-20094 injected subcutaneously once weekly |
| DRUG | Dulaglutide Injection | Dulaglutide injected subcutaneously once weekly |
Timeline
- Start date
- 2025-09-30
- Primary completion
- 2027-03-30
- Completion
- 2027-05-30
- First posted
- 2025-09-05
- Last updated
- 2025-09-05
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07156539. Inclusion in this directory is not an endorsement.